FDA EIR - Unknown Company - September 08, 2017

This FDA inspection report details a Current Good Manufacturing Practice (cGMP) assessment of Merck KGaA, located at Frankfurter Str. 250, Darmstadt, conducted from September 4 to September 8, 2017. The inspection, which covered Quality, Production, Facilities and Equipment, Laboratory, and Material systems, also included a pre-approval inspection for an active pharmaceutical ingredient (API) and evaluation of the firm's controls for distributing APIs and reference standards. The regulatory framework guiding this inspection involved guidelines for API process inspections and drug manufacturing inspections. While no formal FDA-483 Inspectional Observation Form was issued, inspectors conveyed two verbal observations. These indicated that the validation process for a specific API was not up to current standards, and the cleaning validation for another manufacturing process was inadequate. Despite these verbal findings, the overall inspection conclusion was classified as "No Action Indicated" (NAI) for GMP, and approval was recommended for the API covered by the pre-approval inspection. This classification suggests that no formal enforcement actions or immediate mandatory corrective actions were required by the FDA at the time of the report.